Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognost...

Descripción completa

Detalles Bibliográficos
Autores principales: Puzanov, Igor, Subramanian, Poornima, Yatsynovich, Yan V, Jacobs, David M, Chilbert, Maya R, Sharma, Umesh C, Ito, Fumito, Feuerstein, Steven G, Stefanovic, Filip, Switzer, Benjamin, Hicar, Mark D, Curtis, Anne B, Spangenthal, Edward J, Dy, Grace K, Ernstoff, Marc S, Vachhani, Pankit, Page, Brian J, Agrawal, Nikhil, Khunger, Arjun, Kapoor, Ankita, Hattoum, Alexander, Schentag, Jerome J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231054/
https://www.ncbi.nlm.nih.gov/pubmed/34162715
http://dx.doi.org/10.1136/jitc-2021-002553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231054/
https://www.ncbi.nlm.nih.gov/pubmed/34162715
http://dx.doi.org/10.1136/jitc-2021-002553

Ejemplares similares